威尔药业 2025 年第一次临时股东大会 法律意见书 江苏世纪同仁律师事务所 关于南京威尔药业集团股份有限公司 2025 年第一次临时股东大会的法律意见书 致：南京威尔药业集团股份有限公司 1、本次股东大会由董事会召集。2025 年 10 月 29 日，贵公司召开了第三届 董事会第十三次会议，决定于 2025 年 11 月 14 日召开 2025 年第一次临时股东大 会。 2025 年 10 月 30 日，贵公司在上海证券交易所网站（www.sse.com.cn）及 《上海证券报》《证券时报》上刊登了《南京威尔药业集团股份有限公司关于召 开 2025 年第一次临时股东大会的通知》。 本所律师根据相关法律、法规和规范性文件的要求，按照律师行业公认的业 务标准、道德规范和勤勉尽责精神，出具法律意见如下： 一、关于本次股东大会的召集、召开程序和召集人资格 上述会议通知除载明本次股东大会的召开时间、地点、股权登记日、会议召 1 威尔药业 2025 年第一次临时股东大会 法律意见书 根据《中华人民共和国公司法》《中华人民共和国证券法》和中国证券监督 管理委员会《上市公司股东会规则》等法律、法规和规范性文件以及《南京威尔 ...

证券代码：603351 证券简称：威尔药业 公告编号：2025-036 南京威尔药业集团股份有限公司 2025年第一次临时股东大会决议公告 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 11 月 14 日 (二)股东大会召开的地点：南京市玄武区苏宁大道 64 号徐庄软件园研发五区 5 号楼三楼会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 40 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 80,237,358 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份总 | | | 数的比例（%） | 59.2423 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由公司董事会召集，吴仁荣先生主持。会议采用现场投票与网 络投票相结合的表决方式。本次会议的召集、召开程序及表决方式符合《公司法》、 《公司章程》等法律、法规及规范性文件的规定。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 ...

- **Tracking indicators and their calculation** The report uses two indicators: the proportion of large buy order transaction amount and the proportion of net active buy transaction amount. The large buy order transaction amount proportion reflects the buying behavior of large funds. It is calculated by restoring transaction data into buy and sell orders based on transaction sequence numbers, filtering large orders by transaction volume, and computing the proportion of large buy order transaction amounts to the total daily transaction amount. The net active buy transaction amount proportion reflects investors' active buying behavior. It is calculated by identifying whether each transaction is an active buy or sell based on transaction markers, subtracting active sell amounts from active buy amounts, and computing the proportion of net active buy amounts to the total daily transaction amount[7] - **Individual stock tracking** The report provides rankings of stocks based on the 5-day average proportion of large buy order transaction amounts and net active buy transaction amounts. For example, the top-ranked stock for large buy order transaction amount proportion is "海陆重工" with a value of 93.0% and a time-series percentile of 100.0%. Similarly, the top-ranked stock for net active buy transaction amount proportion is "力聚热能" with a value of 21.2% and a time-series percentile of 100.0%[9][10] - **Broad-based index tracking** The report calculates the 5-day average proportions of large buy order transaction amounts and net active buy transaction amounts for major broad-based indices. For instance, the "上证指数" has a large buy order transaction amount proportion of 73.6% (percentile: 66.0%) and a net active buy transaction amount proportion of -4.1% (percentile: 99.6%)[11][12] - **Sector tracking** The report calculates the 5-day average proportions of large buy order transaction amounts and net active buy transaction amounts for various sectors. For example, the "石油石化" sector has a large buy order transaction amount proportion of 78.3% (percentile: 100.0%) and a net active buy transaction amount proportion of 5.0% (percentile: 27.0%)[13] - **ETF tracking** The report ranks ETFs based on the 5-day average proportions of large buy order transaction amounts and net active buy transaction amounts. For example, the top-ranked ETF for large buy order transaction amount proportion is "国泰上证 10 年期国债 ETF" with a value of 93.7% and a time-series percentile of 100.0%. Similarly, the top-ranked ETF for net active buy transaction amount proportion is "国泰上证 10 年期国债 ETF" with a value of 24.7% and a time-series percentile of 84.4%[15][16]

会议资料 二〇二五年十一月 1 / 8 南京威尔药业集团股份有限公司 2025 年第一次临时股东大会会议资料 南京威尔药业集团股份有限公司 （Nanjing Well Pharmaceutical Group Co.,Ltd.） 2025年第一次临时股东大会 南京威尔药业集团股份有限公司 2025 年第一次临时股东大会会议资料 目 录 | 一、2025 年第一次临时股东大会会议须知 | 3 | | --- | --- | | 二、2025 年第一次临时股东大会会议议程 | 5 | | 年第一次临时股东大会会议议案 三、2025 | | | 议案一《关于取消监事会并修订<公司章程>的议案》 7 | | | 议案二《关于修订、制定及废止公司部分治理制度的议案》 8 | | 2 / 8 南京威尔药业集团股份有限公司 2025 年第一次临时股东大会会议资料 南京威尔药业集团股份有限公司 2025年第一次临时股东大会会议须知 为维护南京威尔药业集团股份有限公司（以下简称"公司"）全体股东的合法权益， 确保股东大会的正常秩序和议事效率，根据《中华人民共和国公司法》《中华人民共和 国证券法》《公司章程》及《股东大会议事规则 ...

Core Viewpoint - 威尔药业 is a significant player in the pharmaceutical excipients and synthetic lubricants sector in China, showcasing strong R&D capabilities and product quality advantages. Group 1: Company Overview - 威尔药业 was established on February 18, 2000, and was listed on the Shanghai Stock Exchange on January 30, 2019, with its registered and office locations in Nanjing, Jiangsu Province [1]. - The company primarily engages in the R&D, production, and sales of pharmaceutical excipients and synthetic lubricants, classified under the pharmaceutical and biological industry [1]. Group 2: Financial Performance - In Q3 2025, 威尔药业 reported a revenue of 1.018 billion yuan, ranking 17th among 47 companies in the industry, with the industry leader, 普洛药业, generating 7.764 billion yuan [2]. - The net profit for the same period was 112 million yuan, placing 威尔药业 at 16th in the industry, while the top performer, 浙江医药, achieved a net profit of 867 million yuan [2]. Group 3: Financial Ratios - As of Q3 2025, 威尔药业's debt-to-asset ratio was 31.69%, an increase from 26.48% year-on-year, and above the industry average of 27.75% [3]. - The gross profit margin for Q3 2025 was 28.48%, up from 25.93% year-on-year, but still below the industry average of 35.38% [3]. Group 4: Executive Compensation - The chairman, 吴仁荣, received a salary of 1.0133 million yuan in 2024, reflecting an increase of 22,600 yuan from 2023 [4]. Group 5: Shareholder Information - As of September 30, 2025, 威尔药业 had 6,776 A-share shareholders, a 5.36% increase from the previous period, with an average of 20,000 circulating A-shares held per shareholder, down by 5.09% [5]. - The company is focusing on dual growth drivers from synthetic lubricants and pharmaceutical excipients, with strategic initiatives in high-tech sectors and high-value new products [5].

Core Insights - 威尔药业 reported its Q3 2025 financial results, highlighting a total of 3 institutional investors holding shares, amounting to 16.4695 million shares, which represents 12.16% of the total share capital [1] - The institutional holding percentage decreased by 1.71 percentage points compared to the previous quarter [1] Institutional Investors - The institutional investors include 南京舜泰宗华创业投资合伙企业(有限合伙), 国泰基金管理有限公司-社保基金2103组合, and 国泰佳泰股票专项型养老金产品-招商银行股份有限公司 [1] - The total institutional holding percentage is now at 12.16% [1] Public Funds - A total of 23 public funds were disclosed this period, including 国泰聚优价值灵活配置混合A, 易方达易百智能量化策略混合A, and 广发百发大数据成长混合A [1] Social Security Funds - One social security fund, 国泰基金管理有限公司-社保基金2103组合, reported a decrease in holdings, with a reduction percentage of 0.31% [1]

Core Insights - Will Pharmaceutical (603351.SH) reported a total operating revenue of 1.018 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 1.79% [1] - The net profit attributable to shareholders of the parent company reached 114 million yuan, showing a year-on-year increase of 1.03% [1] - The basic earnings per share stood at 0.84 yuan [1]

Core Insights - The company reported a revenue of 344,518,752.28 yuan for the third quarter of 2025, representing a year-on-year growth of 10.35% [1] - The net profit attributable to shareholders of the listed company was 41,298,570.17 yuan, showing a year-on-year increase of 21.46% [1]

（一）审议通过了《公司 2025 年第三季度报告》 表决结果：同意 7 票，反对 0 票，弃权 0 票。 证券代码：603351 证券简称：威尔药业 公告编号：2025-030 南京威尔药业集团股份有限公司 第三届董事会第十三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 南京威尔药业集团股份有限公司（以下简称"公司"）第三届董事会第十三次会议 于 2025 年 10 月 29 日在公司会议室以现场结合通讯方式召开。本次会议通知已于 2025 年 10 月 24 日以书面方式发出。会议由董事长吴仁荣先生主持，应到董事 7人， 实到董事 7 人。本次会议的召集、召开程序符合《中华人民共和国公司法》及《公 司章程》等相关规定，会议合法有效。 二、董事会会议审议情况 本议案在提交董事会前已经第三届董事会审计委员会第十一次会议审议通过。 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披露的《公 司 2025 年第三季度报告》。 （二）审议通过了《关于取消监事会并修订<公 ...

南京威尔药业集团股份有限公司 募集资金使用管理制度 二○二五年十月 | र | | --- | | 第一章 | 总 则 | 1 | | --- | --- | --- | | 第二章 | 募集资金专户存储 2 | | | 第三章 | 募集资金使用 | 3 | | 第四章 | 募集资金用途的改变 6 | | | 第五章 | 募集资金管理与监督 9 | | | 第六章 | 附 则 | 10 | 南京威尔药业集团股份有限公司 第七条 公司应当审慎选择商业银行并开设募集资金专项账户（以下简称 "专户"），募集资金应当存放于经董事会批准设立的专户集中管 理，专户不得存放非募集资金或用作其他用途。公司存在两次以上 融资的，应当分别设置募集资金专户。 实际募集资金净额超过计划募集资金金额的部分（以下简称"超募 资金"）也存放于募集资金专户管理。 第八条 公司应当在募集资金到账后一个月内与保荐人或者独立财务顾问、 存放募集资金的商业银行（以下简称"商业银行"）签订募集资金 专户存储三方监管协议（以下简称"协议"）并及时公告。协议签 订后，公司可以使用募集资金。协议至少应当包括以下内容： （一） 公司应当将募集资金集中存放于募 ...